BTG plc (LSE: BTG), the specialist healthcare company, today announces that the US Food and Drug Administration (FDA) has approved Varithena™ (polidocanol injectable foam) for the treatment of ...

WEST CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--BTG plc (LSE:BTG), the specialist healthcare company, announced that the U.S. Food and Drug Administration has approved an extension of the post-activation ...

BTG plc: FDA approves Varithena™ (polidocanol injectable foam) for the treatment of patients with varicose veins London, UK, 26 November 2013: BTG plc (LSE: BTG), the specialist healthcare company, ...

OTTAWA, Jan. 26, 2017 /CNW/ - BTG International Canada Inc., part of global specialist healthcare company BTG (LSE: BTG), today announced the Canadian commercial launch of Varithena ™ (polidocanol ...

The US Food and Drug Administration (FDA) has approved BTG's Varithena (polidocanol injectable foam) for the treatment of patients with incompetent veins and visible varicosities of the great ...

BTG has finally got the green light in the USA for Varithena, the UK group's varicose veins treatment. BTG has finally got the green light in the USA for Varithena, the UK group’s varicose veins ...

BTG plc (LSE: BTG), the specialist healthcare company, today announces that Health Canada has issued a Notice of Compliance approving Varithena™ (polidocanol injectable foam), a prescription medicine ...

British pharmaceutical firm BTG has announced the arrival of a new treatment for varicose veins. The company’s product, Varithena, offers a minimally invasive treatment that is capable of dissolving ...

WORTHINGTON, OH, UNITED STATES, June 9, 2026 /EINPresswire.com/ — Akribis Veins & Vitality is educating patients about today’s leading minimally invasive varicose ...

BTG plc, an international specialist healthcare company bringing to market innovative products in specialist areas of medicine, announces that Health Canada has issued a Notice of Compliance approving ...